SCHEMBL7188239

SCHEMBL7188239

CC(=O)O[C@H]1CC[C@H](n2c(=O)n(Cc3ccc(Cl)cc3)c3cc(C#N)ccc32)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
DRD4 P21917 1/20 0.38
P2RX3 P56373 4/20 0.37
CTSS P25774 1/20 0.37
CLPP Q16740 1/20 0.37
CCR2 P41597 1/20 0.37
MDM2 Q00987 1/20 0.37
DRD2 P14416 1/20 0.36
SLC6A4 P31645 1/20 0.36
CCR9 P51686 1/20 0.36
HSD11B1 P28845 1/20 0.36
OPRM1 P35372 1/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP11B2 P19099 1/20 0.35
PDE7A Q13946 1/20 0.35
PDE7B Q9NP56 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188245 1.00 CYP3A4 (0.40) CYP3A4CYP2D6PRMT5WDR77DRD4
SCHEMBL7185752 0.91 CYP3A4 (0.44) CYP3A4CYP2D6PRMT5WDR77DRD4
SCHEMBL7185745 0.91 CYP3A4 (0.44) CYP3A4CYP2D6PRMT5WDR77DRD4
SCHEMBL7190841 0.89 PDE7A (0.42) PRMT5WDR77DRD4PDE7APDE7B
SCHEMBL7190835 0.89 PDE7A (0.42) PRMT5WDR77DRD4PDE7APDE7B
SCHEMBL7190422 0.88 PDE7A (0.49) PRMT5WDR77HSD11B1PDE7APDE7B
SCHEMBL7190418 0.88 PDE7A (0.49) PRMT5WDR77HSD11B1PDE7APDE7B
SCHEMBL7190968 0.87 SMN1; SMN2 (0.42) CYP3A4OPRM1MAPT
SCHEMBL7190975 0.87 SMN1; SMN2 (0.42) CYP3A4OPRM1MAPT
SCHEMBL7179404 0.86 C5AR1 (0.47) CYP3A4CYP2D6OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed